Product theaters provide time for presentation of new research findings on products, showcasing of product details, demonstrations and highlights of new products. These sessions may be promotional or non-promotional but are not eligible for continuing education credits. 

Sunday, April 24, 11:30 AM (CDT)

Delaying Time to Relapse in Adult Patients With Schizophrenia

During this presentation, Kristin Waters, PharmD will discuss how Janssen’s long-acting Injectable (LAI) can delay time to relapse for adult patients with schizophrenia.


Kristin Waters, PharmD, BCPS, BCPP
Assistant Clinical Professor, Department of Pharmacy Practice
University of Connecticut
Storrs, CT



Supported by

Monday, April 25, 12:00 PM (CDT)

Learn More: An oral Treatment Option for Adults with Schizophrenia or Bipolar I Disorder

This program will provide an overview of the clinical data, information for use in clinical practice, and important safety information supporting an oral treatment option for adult patients living with schizophrenia or bipolar I disorder.


Jacob Hanaie, PharmD, APH
Director of Pharmacy
Kedren Acute Psychiatric Hospital and CMHC
Founder and Consulting Clinical Pharmacist
Clinical Pharmacy Interventions
Beverly Hills, CA


Supported by

Monday, April 25, 4:15 PM (CDT)

The Role of Antipsychotic TDM in Clinical Decision Making: The Example of Clozapine

Readily available therapeutic drug monitoring (TDM) of antipsychotic blood levels can provide evidenced-based and personalized psychopharmacologic treatment. Clozapine is the only evidence-based antipsychotic option for treatment resistant schizophrenia and schizophrenia patients with suicidality, with a wealth of data on plasma level response thresholds and the point of futility. For medications such as clozapine, patients and healthcare providers have many situations where TDM is highly relevant in making day-to-day clinical decisions, including differentiating poor adherence with ultrarapid metabolism, and optimizing levels in inadequate responders. During this session, the faculty will discuss the unique place of clozapine for treatment resistant schizophrenia, and the role of TDM in clozapine dosing during titration, and for monitoring ongoing adherence. An open microphone session will follow the presentations.


Jonathan Meyer, MD
Clinical Professor of Psychiatry
University of California, San Diego

Psychopharmacology Consultant
California Department of State Hospitals

Rob Cotes, MD
Director, Clinical and Research Program for Psychosis
Grady Health System

Associate Professor
Emory University School of Medicine
Department of Psychiatry and Behavioral Sciences

Physician Expert, SMI Adviser

Deanna Kelly, PharmD, BCPP
MPower Professor of Psychiatry, University of Maryland Strategic Partnership: MPowering the State
Acting Director and
Chief, Treatment Research Program (TRP)
Maryland Psychiatric Research Center (MPRC)
University of Maryland School of Medicine

Megan Ehret, PharmD, MS, BCPP
Department of Pharmacy Practice and Science
University of Maryland School of Pharmacy
SMI Advisor, Pharmacist Consultant


Rob Cotes has received research funding (to instituition) from Otsuka, Lunbeck, Roche and Alkermes. He is a consultant to Saladax Biomedical and the American Psychaitric Association.

Deanna Kelly serves as a consultant for Sunovian, Lyndra Therapeutics, and Alkermes. She has received compensation from Saladax Biomedical for presenting at CPNP.

Jonathan Meyer is a consultant to Acadia Pharmaceuticals, Alkermes, Allergan, Intra-Cellular Therapies, and Neurocrine, Noven Pharmaceuticals Inc., Otsuka America Inc., Sunovion Pharamceuticals, and Teva Pharmaceutical Industries. He has received compensation from Saladax Biomedicalfor presenting at CPNP.

Megan Ehret is a Lexi-Comp Consultant/Reviewer. She has received compensation from Saladax Biomedical for presenting at CPNP.

Supported by